AstraZeneca blood clot treatment meets trial endpoint

AstraZeneca on Friday said its Danicopan add-on anti blood-clotting drug had met a primary endpoint in a phase III trial.

The company said the treatment for paroxysmal nocturnal haemoglobinu (PNH) - a rare, chronic, progressive and potentially life-threatening blood disorder - showed positive high-level results in the trial.

PNH is characterised by red blood cell destruction within blood vessels (also known as intravascular haemolysis) and white blood cell and platelet activation, which can result in thrombosis, or blood clots.

Reporting by Frank Prenesti at Sharecast.com